GlassScriptPhysician profile
William S Davis
NPI 1659581270
$4,677.93
in general payments reported to CMS, 2019-2025
15 companies · $985 in 2025
The $985 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $800 · 2022: $655 · 2023: $807 · 2024: $1,432 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,223.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,268.01 | 2021-2025 | Caplyta |
| Alkermes, INC. | $666.68 | 2021-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $451.64 | 2021-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $403.42 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $323.42 | 2024-2025 | Ingrezza |
| Abbvie INC. | $308.07 | 2023-2025 | |
| Axsome Therapeutics, INC. | $296.86 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $275.77 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $265.62 | 2021-2022 | |
| Corium, LLC | $191.52 | 2022 | |
| Janssen Pharmaceuticals, INC | $99.62 | 2023 | Spravato |
| Teva Pharmaceuticals USA, INC. | $54.01 | 2025 | Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $33.86 | 2024-2025 | Fanapt |
| Lundbeck LLC | $19.98 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.45 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.